welcomes you to the new, improved website!Egyud and colleagues evaluated plasma levels of circulating tumor (ct)DNA in patients with esophageal adenocarcinoma, ranging from stage I to stage IV. The quantity of ctDNA and likelihood of ctDNA detection was greater at later stages, suggesting that it may be challenging to use for early-stage diagnosis. However, changes in ctDNA levels were indicative of response to therapy and recurrence, and the authors conclude that they may serve as a dynamic biomarker to monitor a patient’s response to treatment.
You are here:
Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma
Submitted by: Emily Robinson
Source: The Annals of Thoracic Surgery
Source URL: https://doi.org/10.1016/j.athoracsur.2019.04.004
Keywords:
Author(s): Matthew Egyud, Mohamedtaki Tejani, Arjun Pennathur, James Luketich, Praveen Sridhar, Emiko Yamada, Anders Ståhlberg, Stefan Filges, Paul Krzyzanowski, Jennifer Jackson, Irina Kalatskaya, Wei Jiao, Gradon Nielsen, Zhongren Zhou, Virginia Litle, Lincoln Stein, Tony Godfrey
